Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Anna G Turkina, Prof., MD, Oleg Shukhov, MDPhD, Ekaterina Chelysheva, MDPhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD

Blood (2017) 130 (Supplement 1): 895.

https://doi.org/10.1182/blood.V130.Suppl_1.895.895

Published: 2017

Journal Articles

High Prevalence of Peripheral Artery Occlusive Disease (PAOD) Among Patients with Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors (TKIs): A Cross-Sectional Study

Thanawat Rattanathammethee, MD, Adisak Tantiworawit, MD, Ekarat Rattarittamrong, MD, Chatree Chai-Adisaksopha, MD, Sasinee Hantrakool, MD, Arintaya Phrommintikul, MD, Siriluck Gunaparn, RN, Lalita Norasetthada, MD

Blood (2015) 126 (23): 5140.

https://doi.org/10.1182/blood.V126.23.5140.5140

Published: 2015

Journal Articles

Peripheral Arterial Occlusive Disease (PAOD) In Chronic Phase Chronic Myeloid Leukemia Patients Treated With Nilotinib

Young-Woo Jeon, M.D., Sung-Eun Lee, M.D., Soo-Young Choi, Soo-Hyun Kim, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 4018.

https://doi.org/10.1182/blood.V122.21.4018.4018

Published: 2013

Journal Articles

Elevated Risk of Peripheral Artery Occlusive Disease (PAOD) in Nilotinib Treated Chronic Phase Chronic Myeloid Leukemia (CML) Patients Assessed by Ankle-Brachial-Index (ABI) and Duplex Ultrasonography

Michaela Schwarz, MD, Theo D. Kim, MD, Tristan Mirault, Peggy Grille, Delphine Rea, MD, PhD, Ruhdja Lindhorst, Herve Dombret, MD, Ivo Buschmann, Wilhelm Haverkamp, Bernd Doerken, Philipp le Coutre, MD

Blood (2012) 120 (21): 914.

https://doi.org/10.1182/blood.V120.21.914.914

Published: 2012

Journal Articles

Analysis of Clinical Arterial and Metabolic Parameters in Chronic Phase CML Patients On Nilotinib in a Single Center Cohort

Hélène Labussière-Wallet, MD, Yann Guillermin, MD, Madeleine Etienne, CRA, Anne-Claire Barale, Caroline Serrier, MD, Isabelle Tigaud, MD, Sandrine Hayette, Oriane Le Borgne, CRA, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Fiorenza Barraco, MD, Mauricette Michallet, MD, PhD, Franck E. Nicolini, MD, PhD

Blood (2012) 120 (21): 3756.

https://doi.org/10.1182/blood.V120.21.3756.3756

Published: 2012

Journal Articles

Intraarterial Versus Intramuscular Delivery of Autologous Bone Marrow Blood to Patients with Critical Limb Ischemia

Martin Mistrik, Juraj Madaric, MD, Andrej Klepanec, MD, Ingrid Olejarova, MD, Marcela Skrakova, MD

Blood (2011) 118 (21): 2999.

https://doi.org/10.1182/blood.V118.21.2999.2999

Published: 2011

Journal Articles

A Bone Marrow Population Containing Both Hematopoietic and Mesenchymal Stem Cells Constitutively Expressing Genes Pairs For: SDF1-CXCR4, CX3CL-CXCR1 and for VEGF Improves Vascularization When Implanted to Ischemic Legs.

A. Lange, W. Witkiewicz, D. Dlubek, L. Maslowski, D. Drabczak-Skrzypek, E. Jaskula, B. Szymczak, D. Duda, J. Lange

Blood (2004) 104 (11): 4178.

https://doi.org/10.1182/blood.V104.11.4178.4178

Published: 2004

NARROW

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

High Prevalence of Peripheral Artery Occlusive Disease (PAOD) Among Patients with Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors (TKIs): A Cross-Sectional Study

Peripheral Arterial Occlusive Disease (PAOD) In Chronic Phase Chronic Myeloid Leukemia Patients Treated With Nilotinib

Elevated Risk of Peripheral Artery Occlusive Disease (PAOD) in Nilotinib Treated Chronic Phase Chronic Myeloid Leukemia (CML) Patients Assessed by Ankle-Brachial-Index (ABI) and Duplex Ultrasonography

Analysis of Clinical Arterial and Metabolic Parameters in Chronic Phase CML Patients On Nilotinib in a Single Center Cohort

Intraarterial Versus Intramuscular Delivery of Autologous Bone Marrow Blood to Patients with Critical Limb Ischemia

A Bone Marrow Population Containing Both Hematopoietic and Mesenchymal Stem Cells Constitutively Expressing Genes Pairs For: SDF1-CXCR4, CX3CL-CXCR1 and for VEGF Improves Vascularization When Implanted to Ischemic Legs.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only